Stock APLLTD ALEMBIC PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Alembic Pharmaceuticals Limited

Equities

APLLTD

INE901L01018

Pharmaceuticals

Market Closed - NSE India S.E.
Other stock markets
 07:40:29 2024-07-09 am EDT 		5-day change 1st Jan Change
973.6 INR -1.24% Intraday chart for Alembic Pharmaceuticals Limited -0.02% +28.21%
Jul. 09 Indian Equities Hit New Closing Highs Led by Auto Stocks MT
Jul. 09 Alembic Pharmaceuticals Gets US FDA Final Nod for Bromfenac Ophthalmic Solution MT

Valuation

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026 2027
Capitalization 1 100,715 189,674 145,771 97,564 193,575 191,384 - -
Enterprise Value (EV) 1 117,382 190,614 152,248 103,100 196,614 190,548 188,083 182,159
P/E ratio 12.1 x 15.9 x 26.7 x 28.5 x 31.4 x 27.3 x 22 x 17.7 x
Yield 1.31% 1.45% 1.35% 1.61% 1.12% 0.88% 1.15% 2.07%
Capitalization / Revenue 2.19 x 3.52 x 2.75 x 1.73 x 3.11 x 2.75 x 2.46 x 2.22 x
EV / Revenue 2.55 x 3.53 x 2.87 x 1.82 x 3.16 x 2.74 x 2.42 x 2.11 x
EV / EBITDA 9.6 x 12.2 x 17.4 x 14.6 x 21.1 x 16.5 x 13.5 x 10.4 x
EV / FCF -52.5 x 23.7 x 120 x 36.8 x 41.3 x 37.7 x 26.5 x 20.6 x
FCF Yield -1.9% 4.22% 0.83% 2.72% 2.42% 2.65% 3.78% 4.86%
Price to Book 3.13 x 3.7 x 2.79 x 2.23 x 4.02 x 3.58 x 3.21 x 2.78 x
Nbr of stocks (in thousands) 188,516 196,563 196,563 196,563 196,563 196,563 - -
Reference price 2 534.2 965.0 741.6 496.4 984.8 973.6 973.6 973.6
Announcement Date 4/23/20 5/4/21 5/2/22 5/5/23 5/9/24 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026 2027
Net sales 1 46,058 53,931 53,058 56,526 62,286 69,473 77,678 86,262
EBITDA 1 12,230 15,576 8,742 7,084 9,334 11,581 13,944 17,490
EBIT 1 10,657 13,741 5,874 4,329 6,607 8,573 10,736 13,756
Operating Margin 23.14% 25.48% 11.07% 7.66% 10.61% 12.34% 13.82% 15.95%
Earnings before Tax (EBT) 1 9,998 13,681 6,201 3,855 6,328 8,368 10,548 14,075
Net income 1 8,291 11,781 5,457 3,420 6,158 6,997 8,640 11,160
Net margin 18% 21.84% 10.28% 6.05% 9.89% 10.07% 11.12% 12.94%
EPS 2 43.98 60.81 27.76 17.40 31.33 35.70 44.24 55.11
Free Cash Flow 1 -2,235 8,039 1,267 2,805 4,757 5,054 7,100 8,850
FCF margin -4.85% 14.91% 2.39% 4.96% 7.64% 7.27% 9.14% 10.26%
FCF Conversion (EBITDA) - 51.61% 14.5% 39.6% 50.97% 43.64% 50.92% 50.6%
FCF Conversion (Net income) - 68.23% 23.22% 82.03% 77.25% 72.23% 82.18% 79.29%
Dividend per Share 2 7.000 14.00 10.00 8.000 11.00 8.575 11.24 20.19
Announcement Date 4/23/20 5/4/21 5/2/22 5/5/23 5/9/24 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3 2025 Q4
Net sales 1 12,717 14,157 12,621 14,750 15,090 14,064 14,862 15,949 16,306 15,170 16,115 16,962 17,476 17,048
EBITDA 1 2,557 1,601 146.5 2,327 2,488 2,122 1,987 2,082 2,663 2,601 2,717 3,200 3,373 3,124
EBIT 1 1,997 370.2 - 1,650 1,822 1,381 - 1,407 1,969 1,906 1,958 2,234 2,415 2,384
Operating Margin 15.7% 2.61% - 11.19% 12.08% 9.82% - 8.82% 12.07% 12.56% 12.15% 13.17% 13.82% 13.98%
Earnings before Tax (EBT) 1 1,967 405.9 -601.6 1,530 1,681 1,246 1,298 1,346 1,846 1,832 1,941 2,431 2,609 2,360
Net income 1 1,764 354.6 -658.8 1,334 1,219 1,526 1,206 1,366 1,804 1,782 1,665 1,884 2,033 1,873
Net margin 13.87% 2.5% -5.22% 9.04% 8.08% 10.85% 8.11% 8.56% 11.07% 11.75% 10.33% 11.11% 11.63% 10.99%
EPS 2 8.980 1.800 - 6.780 6.200 - - - 9.180 9.070 8.460 - - -
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 2/10/22 5/2/22 8/4/22 11/11/22 2/1/23 5/5/23 8/4/23 11/7/23 2/5/24 5/9/24 - - - -
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026 2027
Net Debt 1 16,667 941 6,477 5,536 3,039 - - -
Net Cash position 1 - - - - - 836 3,301 9,224
Leverage (Debt/EBITDA) 1.363 x 0.0604 x 0.7409 x 0.7815 x 0.3256 x - - -
Free Cash Flow 1 -2,235 8,039 1,267 2,805 4,757 5,054 7,100 8,850
ROE (net income / shareholders' equity) 27.9% 28.2% 10.5% 7.12% 13.4% 13.8% 15.3% 17.6%
ROA (Net income/ Total Assets) - 18.6% 7.89% 5.14% - - - -
Assets 1 - 63,489 69,152 66,525 - - - -
Book Value Per Share 2 171.0 261.0 266.0 222.0 245.0 272.0 304.0 351.0
Cash Flow per Share 2 23.80 75.50 27.60 36.80 40.90 49.20 43.10 65.20
Capex 1 6,726 6,595 4,256 4,434 3,275 2,878 2,901 3,375
Capex / Sales 14.6% 12.23% 8.02% 7.84% 5.26% 4.14% 3.73% 3.91%
Announcement Date 4/23/20 5/4/21 5/2/22 5/5/23 5/9/24 - - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Alembic Pharmaceuticals Limited

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
14
Last Close Price
973.6 INR
Average target price
981.2 INR
Spread / Average Target
+0.78%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ALEMBIC PHARMACEUTICALS LIMITED Stock Alembic Pharmaceuticals Limited
+28.21% 2.32B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+59.97% 827B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+38.38% 634B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.18% 350B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.61% 319B
ABBVIE INC. Stock AbbVie Inc.
+8.44% 294B
ASTRAZENECA PLC Stock AstraZeneca PLC
+12.68% 240B
NOVARTIS AG Stock Novartis AG
+14.40% 221B
ROCHE HOLDING AG Stock Roche Holding AG
+0.04% 219B
AMGEN INC. Stock Amgen Inc.
+9.68% 167B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. APLLTD Stock
  4. Financials Alembic Pharmaceuticals Limited